Trials / Completed
CompletedNCT03561181
Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 3 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate safety of S.flexneriza-S.sonnei Bivalent Conjugate Vaccine in healthy volunteers aged above 3 Months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine | Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine. |
| BIOLOGICAL | S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine | Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine. |
Timeline
- Start date
- 2017-07-18
- Primary completion
- 2018-01-28
- Completion
- 2018-02-08
- First posted
- 2018-06-19
- Last updated
- 2018-10-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03561181. Inclusion in this directory is not an endorsement.